Cargando…

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

INTRODUCTION: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with prev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Zhenggang, Ducreux, Michel, Abou-Alfa, Ghassan K., Merle, Philippe, Fang, Weijia, Edeline, Julien, Li, Zhiwei, Wu, Lihua, Assenat, Eric, Hu, Sheng, Rimassa, Lorenza, Zhang, Tao, Blanc, Jean-Frédéric, Pan, Hongming, Ross, Paul, Yen, Chia-Jui, Tran, Albert, Shao, Guoliang, Bouattour, Mohamed, Chen, Yajin, Meyer, Tim, Hou, Jinlin, Tougeron, David, Bai, Yuxian, Hou, Ming-Mo, Meng, Zhiqiang, Wu, John, Li, Vincent, Chica-Duque, Sandra, Cheng, Ann-Lii
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982342/ https://www.ncbi.nlm.nih.gov/pubmed/36872927 http://dx.doi.org/10.1159/000527175

Ejemplares similares

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
por: El-Khoueiry, Anthony B., et al.
Publicado: (2022)

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial
por: Qin, Shukui, et al.
Publicado: (2023)

Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
por: Huo, Liman, et al.
Publicado: (2023)

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
por: Shen, Lin, et al.
Publicado: (2020)

RVX 208
Publicado: (2012)

Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
por: Zhu, Chunting, et al.
Publicado: (2022)

Cantata no. 208 Was mir behagt : Hunt cantata /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1986)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

Tislelizumab-related enteritis successfully treated with adalimumab: A case report
por: Chen, Na, et al.
Publicado: (2022)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
por: Budha, Nageshwar, et al.
Publicado: (2022)

Directed Flow in 158 A GeV $^{208}Pb$ + $^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (1998)

Particle production in 158.A GeV $^{208}$Pb + $^{208}$Pb collisions
por: Awes, T C
Publicado: (1999)

Compton scattering on $^{208}$Pb
por: Alberico, W M, et al.
Publicado: (1982)

Oral Presentations 208–237
Publicado: (2001)

Novel Therapies for Hepatocellular Carcinoma
por: Rimassa, Lorenza
Publicado: (2020)

MicroRNA-208a-3p promotes osteosarcoma progression via targeting PTEN
por: Fu, Yutuo, et al.
Publicado: (2020)

Competition between Allowed and First-Forbidden $β$ Decay: The Case of $^{208}$Hg$→^{208}$Tl
por: Carroll, R J, et al.
Publicado: (2020)

Freeze-Out Parameters in Central 158 AGeV $^{208}Pb$ + $^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (1999)

Direct Photon Production in 158 A GeV $^{208}Pb+^{208}Pb$ collisions
por: Aggarwal, M.M., et al.
Publicado: (2001)

Direct Photon Production in 158 A GeV $^{208}$ PB+$^{208}$ PB Collisions
por: Peitzmann, Thomas
Publicado: (2001)

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
por: Ye, Dingwei, et al.
Publicado: (2020)

Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody
por: Zhang, Lin, et al.
Publicado: (2022)

Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers
por: Zheng, Xiaojing, et al.
Publicado: (2023)

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
por: Tam, Constantine, et al.
Publicado: (2023)

Measurement of conversion electrons with the $^{208}Pb(p,n)^{208}Bi$ reaction and derivation of the shell model proton neutron hole interaction from the properties of $^{208}Bi$
por: Maier, K H, et al.
Publicado: (2007)

$\Delta^{++}$ production in 158 A GeV $^{208}Pb+^{208}Pb$ interactions at the CERN SPS
por: Aggarwal, M M, et al.
Publicado: (2000)

Interferometry of direct photons in central $^{208}$Pb+$^{208}$Pb collisions at 158A GeV
por: Aggarwal, M M, et al.
Publicado: (2004)

Observation of Direct Photons in Central 158 A GeV $^{208}Pb+^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (2000)

Competition between allowed and first-forbidden $β$ decays of $^{208}$At and expansion of the $^{208}$Po level scheme
por: Brunet, M, et al.
Publicado: (2021)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Health Tract No. 208: Restless Nights
Publicado: (1864)

Health Tract No. 208: Restless Nights
Publicado: (1865)

Centrality Dependence of Neutral Pion Production in 158 A GeV $^{208}Pb +^{208}Pb$ Collisions
por: Aggarwal, M.M., et al.
Publicado: (1998)

Scaling of Particle and Transverse Energy Production in 208Pb+208Pb collisions at 158 A GeV
por: Aggarwal, M.M., et al.
Publicado: (2001)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
por: Cheng, Lili, et al.
Publicado: (2021)

Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa
por: Abou-Alfa, Ghassan
Publicado: (2020)

Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report
por: Tang, Wen‐Fang, et al.
Publicado: (2021)

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
por: Ding, Yuan, et al.
Publicado: (2021)

Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report
por: Qu, Fanjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_blq0o1iceu9lqr0jgb3mii6rpn